| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AbbVie M14-239 | 18-49 | locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible) |
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| AcceleRET-Lung | 20-21 | This clinical trial is recruiting people with non-small cell lung cancer (NSCLC) that cannot be removed through surgery or that has spread to other parts of the body. |
AcceleRET-Lung: A clinical trial to compare a medicine called pralsetinib with standard-of-care chemotherapy treatments in people with non-small cell lung cancer (NSCLC). |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Add-Asprin | 16-19 | Non-metastatic breast, colorectal, gastro-oesophagal or prostate cancer which can be treated and potentially cured. |
The purpose of this study is to evaluate the the effects of aspirin on disease recurrence and survival in patients who have had primary curative therapy for common non-metastatic solid tumours. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ALEXANDRA/IMpassion030 | 17-15 (WO39391 / BIG 16-05) | Early stage breast cancer |
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Astellas 8951-CL-5201 | CTRIAL-IE 18-44 | Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma |
This study will asses the antitumor activity and safety of Zolbetuximab (IMAB362) in combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BCNI GMI-1271-301 | 21-08 | Relapsed/Refractory Acute Myeloid Leukemia (AML) |
This Study is to Determine the Effficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukaemia |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BI Afatinib Trial | CTRIAL-IE 18-23 | To determine the maximum tolerated dose (MTD), safety, and efficacy of afatinib monotherapy |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BMS CA045-001 | CTRIAL-IE 18-51 | Melanoma. |
This study will evaluate the efficacy of NKTR-214 Combined with Nivolumab Versus Nivolumab |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BMS CA209-8FC | CTRIAL-IE 19-13 | Melanoma. |
The study will compare the pharmacokinetics of BMSCHO1-Nivolumab Process D to Nivolumab Process C |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| BMS CA209-8HW | 18-08 | Metastatic colorectal cancer (mCRC) |
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA045-001 | 18-51 | Previously untreated or unresectable or Metastatic Melanoma |
The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA209-73L / CheckMate 73L | 19-25 | Participants with previously untreated Locally Advanced Non-Small Cell Lung Cancer. |
This study is looking at adding nivolumab to chemoradiotherapy and comparing it to chemoradiotherapy alone. It is also comparing 3 different immunotherapy treatments to have after these first treatments. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA209-7FL | 19-35 | high-risk, estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) early stage breast cancer |
The purpose of this trial is to evaluate the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CA224-104 | 21-12 | Participants with previously untreated Stage IV Non-Small Cell Lung Cancer. |
The objective of the trial is to confirm the dose safety of combination relatlimab and nivolumab plus chemo and to compare the progression free survival for patients with untreated stage IV Non-Small Cell Lung Cancer or Recurrent Non-small Cell Lung Cancer. |
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| CARABELA | 20-25 | High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer with an indication of neoadjuvant therapy |
To compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients |